| Id |
Subject |
Object |
Predicate |
Lexical cue |
| T544 |
0-35 |
Sentence |
denotes |
nAbs Derived from COVID-19 Patients |
| T545 |
36-221 |
Sentence |
denotes |
Patients who have recovered from SARS-CoV-2 infection are one potential source of nAbs (Chen et al., 2020a, Ju et al., 2020, Walls et al., 2020, Wölfel et al., 2020, Yuan et al., 2020). |
| T546 |
222-452 |
Sentence |
denotes |
In an effort to obtain these nAbs, scientists sorted RBD-specific memory B cells and cloned their heavy and light variable regions to express recombinant forms of the corresponding antibodies (Chen et al., 2020a, Ju et al., 2020). |
| T547 |
453-614 |
Sentence |
denotes |
Four of the antibodies produced in these studies (31B5, 32D4, P2C-2F6, P2C-1F11) showed high neutralizing potential in vitro, and all inhibited ACE2-RBD binding. |
| T548 |
615-734 |
Sentence |
denotes |
Successful antibody-mediated neutralization of SARS-CoV-2 seemed to be dependent on the inhibition of ACE2/RBD binding. |
| T549 |
735-929 |
Sentence |
denotes |
However, Chen et al. showed that nearly all antibodies derived from serum of 26 recovered patients bound to S1 and RBD, with only three actually inhibiting ACE2/RBD binding (Chen et al., 2020a). |
| T550 |
930-1167 |
Sentence |
denotes |
Of note, a SARS-CoV-1-derived neutralizing antibody (47D11) (Wang et al., 2020a) and a single-chain antibody against SARS-CoV-2 (n3130) (Wu et al., 2020c) have also been shown to neutralize SARS-CoV-2 without inhibiting ACE2/RBD binding. |
| T551 |
1168-1258 |
Sentence |
denotes |
Thus, blocking this interaction may not be a prerequisite for an effective SARS-CoV-2 nAb. |
| T552 |
1259-1503 |
Sentence |
denotes |
The generation of a hybridoma producing a monoclonal nAb against SARS-CoV-2 provides the potential for a therapeutic Ab that can be directly administered to patients to block ongoing infection and potentially even as a prophylactic (Figure 6D). |
